Brief: Cytokinetics Participates In FDA Late Cycle Meeting For NDA For Aficamten - SEC Filing

Cytokinetics, Incorporated

16/09/2025 21:26

Sept 16 (Reuters) - SEC Filing:

CYTOKINETICS INC - ON SEPT 15, CO PARTICIPATES IN FDA LATE CYCLE MEETING FOR NDA FOR AFICAMTEN - SEC FILING

CYTOKINETICS INC - PDUFA TARGET ACTION DATE FOR AFICAMTEN NDA IS DEC 26, 2025 - SEC FILING

CYTOKINETICS - CONTINUES TO EXPECT DIFFERENTIATED LABEL & RISK MITIGATION PROFILE FOR AFICAMTEN IF APPROVED BY FDA - SEC FILING

Source text: [ID:n0001193125-25-204991]

Further company coverage: CYTK.O

 ((Reuters.Briefs@thomsonreuters.com;))